BioStock: Respiratorius gets green light for PK study
Respiratorius is ready to initiate a pharmacokinetic phase I study with VAL001. The aim is to investigate the candidate’s release profile prior to a pivotal phase III study and show how VAL001 differs from other products, which Respiratorius considers important for a partnership agreement. The PK study recently received the necessary regulatory approval, and once the Ethics Committee has given its final decision, the study can begin. BioStock contacted CEO Johan Drott for comment.
Read the full article at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se